In line with this, AMPK activation inhibits CFTR in Madin-Darby canine kidney (MDCK) cells [165] as well as decreases cystogenesis in murine models of ADPKD [165,166], suggesting a potential role for pharmacological AMPK activation in the treatment of ADPKD [165,166]. Here, PRKAA1 is linked to autosomal dominant polycystic kidney disease.